Literature DB >> 2559750

A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).

J E Gilmour1, J M Senior, N R Burns, M P Esnouf, K Gull, S M Kingsman, A J Kingsman, S E Adams.   

Abstract

The self-assembly properties of a protein encoded by the yeast retrotransposon Ty can be exploited to produce large amounts of recombinant, particulate fusion proteins as hybrid Ty virus-like particles (Ty-VLPs). This system has now been adapted to allow the release of the additional protein by incorporation of a protease cleavage site between the yeast carrier protein and the protein of interest. The purification of the additional protein is facilitated by exploiting the ease with which Ty-VLPs can be purified from other yeast cell components due to their particulate nature. We have used this modified system to produce hybrid particles containing the HIV-1 p24 protein downstream of the recognition sequence for the blood coagulation factor Xa. The p24 was released from the particles by proteolytic cleavage and rapidly separated from the residual particulate material using centrifugation and standard chromatography techniques. This procedure has been used to purify milligram quantities of HIV-1 p24 protein that reacts with anti-p24 sera and elicits the production of p24-specific antibodies in experimental animals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559750     DOI: 10.1097/00002030-198911000-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17.

Authors:  Y Morikawa; T Kishi; W H Zhang; M V Nermut; D J Hockley; I M Jones
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

3.  Production and purification of hybrid Ty-VLPs.

Authors:  N R Burns; J E Gilmour; S M Kingsman; A J Kingsman; S E Adams
Journal:  Mol Biotechnol       Date:  1994-04       Impact factor: 2.695

4.  Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

Authors:  R Wagner; H Fliessbach; G Wanner; M Motz; M Niedrig; G Deby; A von Brunn; H Wolf
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

Authors:  J C Griffiths; E L Berrie; L N Holdsworth; J P Moore; S J Harris; J M Senior; S M Kingsman; A J Kingsman; S E Adams
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

7.  Exploiting the yeast L-A viral capsid for the in vivo assembly of chimeric VLPs as platform in vaccine development and foreign protein expression.

Authors:  Frank Powilleit; Tanja Breinig; Manfred J Schmitt
Journal:  PLoS One       Date:  2007-05-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.